Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 10/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24617110 | 0.82 | ESR2 (0.40) | IMPDH2IMPDH1ARALDH1A1SLC22A12 | |
| SCHEMBL24617488 | 0.80 | AR (0.43) | IMPDH2IMPDH1ARSLC22A12SLC22A6 | |
| SCHEMBL7685399 | 0.80 | ALDH1A1 (0.34) | IMPDH2IMPDH1ALDH1A1TSHR | |
| SCHEMBL151936 | 0.80 | IMPDH2 (0.64) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL5517816 | 0.80 | ALDH1A1 (0.48) | KDM4EALDH1A1GAAMAPTTSHR | |
| SCHEMBL29489135 | 0.80 | IMPDH2 (0.64) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL24617494 | 0.78 | KIF11 (0.38) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL26259653 | 0.78 | PNMT (0.39) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL11193357 | 0.78 | IMPDH2 (0.61) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL19961091 | 0.77 | SLC22A12 (0.40) | IMPDH2IMPDH1ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183191-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183191-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20220220084-A1 | ORGANIC COMPOUND, ELECTRONIC COMPONENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-9905776-B2 | Pyrene-based compound and organic light-emitting diode comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9905776-B2 | Pyrene-based compound and organic light-emitting diode comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-27 | — | — | US | disclosed |
| US-8809579-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140183468-A1 | PYRENE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-03 | — | — | US | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| WO-2007054770-A2 | PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE | PFIZER LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105909-A1 | Compounds useful in therapy | GNRHR, OPRK1, CBR3 | IMPDH2 4822/4885IMPDH1 4791/4885AR 468/4885 |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | CBR3, GNRHR, RXFP3 | IMPDH2 4777/4885IMPDH1 4694/4885AR 563/4885 |
| US-20230183191-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | CNOT1, NXF1, NR2E1 | IMPDH2 3651/4885IMPDH1 3520/4885AR 61/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | IMPDH2 4056/4885IMPDH1 3523/4885AR 1141/4885 |
| US-20220220084-A1 | ORGANIC COMPOUND, ELECTRONIC COMPONENT AND ELECTRONIC APPARATUS | EXOC4, CYBA, SCO2 | IMPDH2 3476/4885IMPDH1 4064/4885AR 4279/4885 |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | IMPDH2 206/4885IMPDH1 166/4885AR 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.